SCHEMBL6568355

SCHEMBL6568355

O=C(N/N=C\c1cc(O)ccc1O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.69
MAOA P21397 1/20 0.69
MAOB P27338 1/20 0.69
SIRT1 Q96EB6 1/20 0.67
GCGR P47871 1/20 0.63
MGAM O43451 2/20 0.62
GAA P10253 1/20 0.62
SI P14410 1/20 0.62
MGAM2 Q2M2H8 1/20 0.62
RAB9A P51151 3/20 0.59
NPC1 O15118 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HTT P42858 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 1/20 0.57
NTRK1 P04629 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6568358 1.00 KDM1A (0.69) KDM1AMAOAMAOBSIRT1GCGR
SCHEMBL6569742 0.91 KDM1A (0.79) KDM1AMAOAMAOBSIRT1GCGR
SCHEMBL6569739 0.91 KDM1A (0.79) KDM1AMAOAMAOBSIRT1GCGR
SCHEMBL8343578 0.88 SIRT1 (0.85) KDM1AMAOAMAOBSIRT1GCGR
SCHEMBL8343583 0.88 SIRT1 (0.85) KDM1AMAOAMAOBSIRT1GCGR
SCHEMBL10522610 0.86 RAB9A (0.59) KDM1AMAOAMAOBSIRT1GCGR
SCHEMBL684844 0.86 KDM1A (0.80) KDM1AMAOAMAOBRAB9ANPC1
SCHEMBL6569744 0.86 PIK3CG (0.62) KDM1AMAOAMAOBGAARAB9A
SCHEMBL684973 0.86 PIK3CG (0.62) KDM1AMAOAMAOBGAARAB9A
SCHEMBL10773642 0.86 RAB9A (0.59) KDM1AMAOAMAOBSIRT1GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP claimed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM1A 2684/4885MAOA 1268/4885MAOB 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.